Favipiravir in High-risk COVID-19 Patients

Summary

The study aims to investigate the efficacy of favipiravir in high-risk COVID-19 patients. The study population includes symptomatic mild-to-moderate COVID-19 inpatients, within first 7 days of illness, who are 50 years old and above, and have 1 or more comorbidities. The study is designed as a randomised, open-label, multicenter clinical trial where the patients are randomised 1:1 to groups receiving favipiravir (5 days) versus no favipiravir.

Conditions

• Covid19

Interventions

DRUG

Favipiravir

Day 1: 1800mg BD, day 2-5: 800mg BD

Sponsors & Collaborators

• Enche' Besar Hajjah Khalsom Hospital

  collaborator UNKNOWN

• Jasin Hospital

  collaborator UNKNOWN

• Kepala Batas Hospital

  collaborator OTHER_GOV

• Melaka Hospital

  collaborator UNKNOWN

• Permai Hospital

  collaborator UNKNOWN

• The Queen Elizabeth Hospital

  collaborator OTHER

• Raja Perempuan Zainab II Hospital

  collaborator UNKNOWN

• Raja Permaisuri Bainun Hospital

  collaborator UNKNOWN

• Sultanah Aminah Hospital

  collaborator UNKNOWN

• Hospital Sultanah Nur Zahirah, Kuala Terengganu

  collaborator OTHER_GOV

• Sungai Buloh Hospital

  collaborator UNKNOWN

• Tampin Hospital

  collaborator UNKNOWN

• Tengku Ampuan Afzan Hospital

  collaborator UNKNOWN

• Tuanku Fauziah Hospital

  collaborator UNKNOWN

• Tuanku Jaafar Hospital

  collaborator UNKNOWN

• Tumpat Hospital

  collaborator UNKNOWN

• Institute for Clinical Research

  collaborator OTHER

• Tawau Hospital

  collaborator UNKNOWN

• Hulu Terrengganu Hospital

  collaborator UNKNOWN

• Penang Hospital, Malaysia

  lead OTHER_GOV

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-02-16

Primary Completion

2021-07-01

Completion

2021-07-13

Countries

• Malaysia

Study Locations